Enter Note Done
Go to previous page in this tab
Session
  • Presentation | Oral Presentations - Advances in Incretin Therapy
  • Oral Presentations
  • Share Icon
    Map Icon
    Bookmark Icon
  • 56-OR - A Long-Acting Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist Shows Weight Loss without Nausea or Vomiting [Board No. 56]
    • Schedule
    Notes
  • Location IconBallroom 20D
    8
    Set Timezone

F.K.Knop: Advisory Panel; ; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Novo Nordisk, Sanofi, Consultant; ; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Novo Nordisk, Sanofi, Research Support; ; Novo Nordisk, Zealand Pharma A/S, Speaker's Bureau; ; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Novo Nordisk, Sanofi, Lundbeck. S.Urva: Employee; ; Eli Lilly and Company, Stock/Shareholder; ; Eli Lilly and Company. M.Rettiganti: Employee; ; Eli Lilly and Company, Stock/Shareholder; ; Eli Lilly and Company. C.Benson: Employee; ; Eli Lilly and Company, Stock/Shareholder; ; Eli Lilly and Company. W.Roell: Employee; ; Eli Lilly and Company, Stock/Shareholder; ; Eli Lilly and Company. K.J.Mather: Employee; ; Eli Lilly and Company. A.Haupt: Employee; ; Lilly, Stock/Shareholder; ; Lilly. E.J.Pratt: Employee; ; Eli Lilly and Company.
Type
Theme Area
CME Hrs.
Livestream Session
Main Session
Discussion